請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/36185
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 周綠蘋(Lu-Ping Chow) | |
dc.contributor.author | Yun-Ju Chen | en |
dc.contributor.author | 陳韻如 | zh_TW |
dc.date.accessioned | 2021-06-13T07:53:16Z | - |
dc.date.available | 2015-10-05 | |
dc.date.copyright | 2011-10-05 | |
dc.date.issued | 2011 | |
dc.date.submitted | 2011-07-21 | |
dc.identifier.citation | 1. Jemal, A., R. Siegel, J. Xu, and E. Ward, Cancer statistics, 2010. CA Cancer J Clin, 2010. 60(5): p. 277-300.
2. Jemal, A., F. Bray, M.M. Center, J. Ferlay, E. Ward, and D. Forman, Global cancer statistics. CA Cancer J Clin, 2011. 61(2): p. 69-90. 3. 行政院衛生署, 98年行政院衛生署死因統計系列. 2010. 4. Miller, D.C., K.S. Hafez, A. Stewart, J.E. Montie, and J.T. Wei, Prostate carcinoma presentation, diagnosis, and staging: an update form the National Cancer Data Base. Cancer, 2003. 98(6): p. 1169-78. 5. van der Cruijsen-Koeter, I.W., A.N. Vis, M.J. Roobol, M.F. Wildhagen, H.J. de Koning, T.H. van der Kwast, and F.H. Schroder, Comparison of screen detected and clinically diagnosed prostate cancer in the European randomized study of screening for prostate cancer, section rotterdam. J Urol, 2005. 174(1): p. 121-5. 6. Cancer, N.C.C.f., Prostate Cancer: Diagnosis and Treatment. NICE Clinical Guidelines, 2008. 58. 7. Verma, S. and A. Rajesh, A clinically relevant approach to imaging prostate cancer: review. AJR Am J Roentgenol, 2011. 196(3 Suppl): p. S1-10 Quiz S11-4. 8. Essink-Bot, M.L., H.J. de Koning, H.G. Nijs, W.J. Kirkels, P.J. van der Maas, and F.H. Schroder, Short-term effects of population-based screening for prostate cancer on health-related quality of life. J Natl Cancer Inst, 1998. 90(12): p. 925-31. 9. Thompson, I.M., D.K. Pauler, P.J. Goodman, C.M. Tangen, M.S. Lucia, H.L. Parnes, L.M. Minasian, L.G. Ford, S.M. Lippman, E.D. Crawford, J.J. Crowley, and C.A. Coltman, Jr., Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med, 2004. 350(22): p. 2239-46. 10. Thompson, I.M., D.P. Ankerst, C. Chi, M.S. Lucia, P.J. Goodman, J.J. Crowley, H.L. Parnes, and C.A. Coltman, Jr., Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA, 2005. 294(1): p. 66-70. 11. Huggins, C. and C.V. Hodges, Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin, 1972. 22(4): p. 232-40. 12. Kokontis, J., K. Takakura, N. Hay, and S. Liao, Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation. Cancer Res, 1994. 54(6): p. 1566-73. 42 13. Marberger, M., P.R. Carroll, M.J. Zelefsky, J.A. Coleman, H. Hricak, P.T. Scardino, and L.L. Abenhaim, New treatments for localized prostate cancer. Urology, 2008. 72(6 Suppl): p. S36-43. 14. Russell, P.J. and E.A. Kingsley, Human prostate cancer cell lines. Methods Mol Med, 2003. 81: p. 21-39. 15. Tai, S., Y. Sun, J.M. Squires, H. Zhang, W.K. Oh, C.Z. Liang, and J. Huang, PC3 is a cell line characteristic of prostatic small cell carcinoma. Prostate, 2011. 16. Patil, B.S., G.K. Jayaprakasha, K.N. Chidambara Murthy, and A. Vikram, Bioactive compounds: historical perspectives, opportunities, and challenges. J Agric Food Chem, 2009. 57(18): p. 8142-60. 17. Slimestad, R., T. Fossen, and I.M. Vagen, Onions: a source of unique dietary flavonoids. J Agric Food Chem, 2007. 55(25): p. 10067-80. 18. Ferry, D.R., A. Smith, J. Malkhandi, D.W. Fyfe, P.G. deTakats, D. Anderson, J. Baker, and D.J. Kerr, Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin Cancer Res, 1996. 2(4): p. 659-68. 19. Bischoff, S.C., Quercetin: potentials in the prevention and therapy of disease. Curr Opin Clin Nutr Metab Care, 2008. 11(6): p. 733-40. 20. Hollman, P.C. and M.B. Katan, Absorption, metabolism and health effects of dietary flavonoids in man. Biomed Pharmacother, 1997. 51(8): p. 305-10. 21. Manach, C., G. Williamson, C. Morand, A. Scalbert, and C. Remesy, Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am J Clin Nutr, 2005. 81(1 Suppl): p. 230S-242S. 22. Terao, J., Dietary flavonoids as antioxidants. Forum Nutr, 2009. 61: p. 87-94. 23. Ciz, M., M. Pavelkova, L. Gallova, J. Kralova, L. Kubala, and A. Lojek, The influence of wine polyphenols on reactive oxygen and nitrogen species production by murine macrophages RAW 264.7. Physiol Res, 2008. 57(3): p. 393-402. 24. Galleano, M., S.V. Verstraeten, P.I. Oteiza, and C.G. Fraga, Antioxidant actions of flavonoids: thermodynamic and kinetic analysis. Arch Biochem Biophys, 2010. 501(1): p. 23-30. 25. Sakanashi, Y., K. Oyama, H. Matsui, T.B. Oyama, T.M. Oyama, Y. Nishimura, H. Sakai, and Y. Oyama, Possible use of quercetin, an antioxidant, for protection of cells suffering from overload of intracellular Ca2+: a model experiment. Life Sci, 2008. 83(5-6): p. 164-9. 26. Graf, B.A., P.E. Milbury, and J.B. Blumberg, Flavonols, flavones, flavanones, and human health: epidemiological evidence. J Med Food, 2005. 8(3): p. 281-90. 43 27. Okoko, T. and I.F. Oruambo, Inhibitory activity of quercetin and its metabolite on lipopolysaccharide-induced activation of macrophage U937 cells. Food Chem Toxicol, 2009. 47(4): p. 809-12. 28. Geraets, L., H.J. Moonen, K. Brauers, E.F. Wouters, A. Bast, and G.J. Hageman, Dietary flavones and flavonoles are inhibitors of poly(ADP-ribose)polymerase-1 in pulmonary epithelial cells. J Nutr, 2007. 137(10): p. 2190-5. 29. Hougee, S., A. Sanders, J. Faber, Y.M. Graus, W.B. van den Berg, J. Garssen, H.F. Smit, and M.A. Hoijer, Decreased pro-inflammatory cytokine production by LPS-stimulated PBMC upon in vitro incubation with the flavonoids apigenin, luteolin or chrysin, due to selective elimination of monocytes/macrophages. Biochem Pharmacol, 2005. 69(2): p. 241-8. 30. Boots, A.W., L.C. Wilms, E.L. Swennen, J.C. Kleinjans, A. Bast, and G.R. Haenen, In vitro and ex vivo anti-inflammatory activity of quercetin in healthy volunteers. Nutrition, 2008. 24(7-8): p. 703-10. 31. MacNee, W., Oxidative stress and lung inflammation in airways disease. Eur J Pharmacol, 2001. 429(1-3): p. 195-207. 32. Alexander, R.B., S. Ponniah, J. Hasday, and J.R. Hebel, Elevated levels of proinflammatory cytokines in the semen of patients with chronic prostatitis/chronic pelvic pain syndrome. Urology, 1998. 52(5): p. 744-9. 33. Shoskes, D.A., S.I. Zeitlin, A. Shahed, and J. Rajfer, Quercetin in men with category III chronic prostatitis: a preliminary prospective, double-blind, placebo-controlled trial. Urology, 1999. 54(6): p. 960-3. 34. Engler, R.J., C.M. With, P.J. Gregory, and J.M. Jellin, Complementary and alternative medicine for the allergist-immunologist: where do I start? J Allergy Clin Immunol, 2009. 123(2): p. 309-16. 35. Higa, S., T. Hirano, M. Kotani, M. Matsumoto, A. Fujita, M. Suemura, I. Kawase, and T. Tanaka, Fisetin, a flavonol, inhibits TH2-type cytokine production by activated human basophils. J Allergy Clin Immunol, 2003. 111(6): p. 1299-306. 36. Plaper, A., M. Golob, I. Hafner, M. Oblak, T. Solmajer, and R. Jerala, Characterization of quercetin binding site on DNA gyrase. Biochem Biophys Res Commun, 2003. 306(2): p. 530-6. 37. Li, M. and Z. Xu, Quercetin in a lotus leaves extract may be responsible for antibacterial activity. Arch Pharm Res, 2008. 31(5): p. 640-4. 38. Ono, K., H. Nakane, M. Fukushima, J.C. Chermann, and F. Barre-Sinoussi, Differential inhibitory effects of various flavonoids on the activities of reverse transcriptase and cellular DNA and RNA polymerases. Eur J Biochem, 1990. 190(3): p. 469-76. 44 39. Lamson, D.W. and M.S. Brignall, Antioxidants and cancer, part 3: quercetin. Altern Med Rev, 2000. 5(3): p. 196-208. 40. Vijayababu, M.R., P. Kanagaraj, A. Arunkumar, R. Ilangovan, M.M. Aruldhas, and J. Arunakaran, Quercetin-induced growth inhibition and cell death in prostatic carcinoma cells (PC-3) are associated with increase in p21 and hypophosphorylated retinoblastoma proteins expression. J Cancer Res Clin Oncol, 2005. 131(11): p. 765-71. 41. Gupta, S.C., J.H. Kim, S. Prasad, and B.B. Aggarwal, Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metastasis Rev, 2010. 29(3): p. 405-34. 42. Li, M., J. Wang, J. Jing, H. Hua, T. Luo, L. Xu, R. Wang, D. Liu, and Y. Jiang, Synergistic promotion of breast cancer cells death by targeting molecular chaperone GRP78 and heat shock protein 70. J Cell Mol Med, 2009. 13(11-12): p. 4540-50. 43. Hansen, R.K., S. Oesterreich, P. Lemieux, K.D. Sarge, and S.A. Fuqua, Quercetin inhibits heat shock protein induction but not heat shock factor DNA-binding in human breast carcinoma cells. Biochem Biophys Res Commun, 1997. 239(3): p. 851-6. 44. Elia, G., C. Amici, A. Rossi, and M.G. Santoro, Modulation of prostaglandin A1-induced thermotolerance by quercetin in human leukemic cells: role of heat shock protein 70. Cancer Res, 1996. 56(1): p. 210-7. 45. Koishi, M., N. Hosokawa, M. Sato, A. Nakai, K. Hirayoshi, M. Hiraoka, M. Abe, and K. Nagata, Quercetin, an inhibitor of heat shock protein synthesis, inhibits the acquisition of thermotolerance in a human colon carcinoma cell line. Jpn J Cancer Res, 1992. 83(11): p. 1216-22. 46. Yokoo, T. and M. Kitamura, Unexpected protection of glomerular mesangial cells from oxidant-triggered apoptosis by bioflavonoid quercetin. Am J Physiol, 1997. 273(2 Pt 2): p. F206-12. 47. Levy, J., I. Teuerstein, M. Marbach, S. Radian, and Y. Sharoni, Tyrosine protein kinase activity in the DMBA-induced rat mammary tumor: inhibition by quercetin. Biochem Biophys Res Commun, 1984. 123(3): p. 1227-33. 48. Boutin, J.A., Tyrosine protein kinase inhibition and cancer. Int J Biochem, 1994. 26(10-11): p. 1203-26. 49. van der Woude, H., M.G. Ter Veld, N. Jacobs, P.T. van der Saag, A.J. Murk, and I.M. Rietjens, The stimulation of cell proliferation by quercetin is mediated by the estrogen receptor. Mol Nutr Food Res, 2005. 49(8): p. 763-71. 50. Kumar, R., V. Verma, A. Jain, R.K. Jain, J.P. Maikhuri, and G. Gupta, Synergistic 45 chemoprotective mechanisms of dietary phytoestrogens in a select combination against prostate cancer. J Nutr Biochem, 2010. 51. Fan, P.S., Z.L. Gu, and Z.Q. Liang, Effect of quercetin on adhesion of platelets to microvascular endothelial cells in vitro. Acta Pharmacol Sin, 2001. 22(9): p. 857-60. 52. Navarro-Nunez, L., M.L. Lozano, C. Martinez, V. Vicente, and J. Rivera, Effect of quercetin on platelet spreading on collagen and fibrinogen and on multiple platelet kinases. Fitoterapia, 2010. 81(2): p. 75-80. 53. Hu, Q., M. Noor, Y.F. Wong, P.J. Hylands, M.S. Simmonds, Q. Xu, D. Jiang, and B.M. Hendry, In vitro anti-fibrotic activities of herbal compounds and herbs. Nephrol Dial Transplant, 2009. 24(10): p. 3033-41. 54. Kuriki, Y. and E. Racker, Inhibition of (Na+, K+)adenosine triphosphatase and its partial reactions by quercetin. Biochemistry, 1976. 15(23): p. 4951-6. 55. Yanagida, M., Functional proteomics; current achievements. J Chromatogr B Analyt Technol Biomed Life Sci, 2002. 771(1-2): p. 89-106. 56. Hunter, T.C., N.L. Andon, A. Koller, J.R. Yates, and P.A. Haynes, The functional proteomics toolbox: methods and applications. J Chromatogr B Analyt Technol Biomed Life Sci, 2002. 782(1-2): p. 165-81. 57. Verhelst, S.H. and M. Bogyo, Chemical proteomics applied to target identification and drug discovery. Biotechniques, 2005. 38(2): p. 175-7. 58. Bantscheff, M., A. Scholten, and A.J. Heck, Revealing promiscuous drug-target interactions by chemical proteomics. Drug Discov Today, 2009. 14(21-22): p. 1021-9. 59. Piersma, S.R., M. Labots, H.M. Verheul, and C.R. Jimenez, Strategies for kinome profiling in cancer and potential clinical applications: chemical proteomics and array-based methods. Anal Bioanal Chem, 2010. 397(8): p. 3163-71. 60. Daub, H., Characterisation of kinase-selective inhibitors by chemical proteomics. Biochim Biophys Acta, 2005. 1754(1-2): p. 183-90. 61. Fleischer, T.C., B.R. Murphy, J.S. Flick, R.T. Terry-Lorenzo, Z.H. Gao, T. Davis, R. McKinnon, K. Ostanin, J.A. Willardsen, and J.J. Boniface, Chemical proteomics identifies Nampt as the target of CB30865, an orphan cytotoxic compound. Chem Biol, 2010. 17(6): p. 659-64. 62. Weighardt, F., G. Biamonti, and S. Riva, The roles of heterogeneous nuclear ribonucleoproteins (hnRNP) in RNA metabolism. Bioessays, 1996. 18(9): p. 747-56. 63. Patry, C., L. Bouchard, P. Labrecque, D. Gendron, B. Lemieux, J. Toutant, E. Lapointe, R. Wellinger, and B. Chabot, Small interfering RNA-mediated 46 reduction in heterogeneous nuclear ribonucleoparticule A1/A2 proteins induces apoptosis in human cancer cells but not in normal mortal cell lines. Cancer Res, 2003. 63(22): p. 7679-88. 64. Perrotti, D. and P. Neviani, From mRNA metabolism to cancer therapy: chronic myelogenous leukemia shows the way. Clin Cancer Res, 2007. 13(6): p. 1638-42. 65. Marcinkiewicz, C., W. Galasinski, and A. Gindzienski, EF-1 alpha is a target site for an inhibitory effect of quercetin in the peptide elongation process. Acta Biochim Pol, 1995. 42(3): p. 347-50. 66. Allemand, E., S. Guil, M. Myers, J. Moscat, J.F. Caceres, and A.R. Krainer, Regulation of heterogenous nuclear ribonucleoprotein A1 transport by phosphorylation in cells stressed by osmotic shock. Proc Natl Acad Sci U S A, 2005. 102(10): p. 3605-10. 67. Guil, S., J.C. Long, and J.F. Caceres, hnRNP A1 relocalization to the stress granules reflects a role in the stress response. Mol Cell Biol, 2006. 26(15): p. 5744-58. 68. Siomi, M.C., P.S. Eder, N. Kataoka, L. Wan, Q. Liu, and G. Dreyfuss, Transportin-mediated nuclear import of heterogeneous nuclear RNP proteins. J Cell Biol, 1997. 138(6): p. 1181-92. 69. Buxade, M., J.L. Parra, S. Rousseau, N. Shpiro, R. Marquez, N. Morrice, J. Bain, E. Espel, and C.G. Proud, The Mnks are novel components in the control of TNF alpha biosynthesis and phosphorylate and regulate hnRNP A1. Immunity, 2005. 23(2): p. 177-89. 70. van der Houven van Oordt, W., M.T. Diaz-Meco, J. Lozano, A.R. Krainer, J. Moscat, and J.F. Caceres, The MKK(3/6)-p38-signaling cascade alters the subcellular distribution of hnRNP A1 and modulates alternative splicing regulation. J Cell Biol, 2000. 149(2): p. 307-16. 71. Lee, K.W., N.J. Kang, Y.S. Heo, E.A. Rogozin, A. Pugliese, M.K. Hwang, G.T. Bowden, A.M. Bode, H.J. Lee, and Z. Dong, Raf and MEK protein kinases are direct molecular targets for the chemopreventive effect of quercetin, a major flavonol in red wine. Cancer Res, 2008. 68(3): p. 946-55. 72. Cook, A., F. Bono, M. Jinek, and E. Conti, Structural biology of nucleocytoplasmic transport. Annu Rev Biochem, 2007. 76: p. 647-71. 73. Bevilacqua, E., X. Wang, M. Majumder, F. Gaccioli, C.L. Yuan, C. Wang, X. Zhu, L.E. Jordan, D. Scheuner, R.J. Kaufman, A.E. Koromilas, M.D. Snider, M. Holcik, and M. Hatzoglou, eIF2alpha phosphorylation tips the balance to apoptosis during osmotic stress. J Biol Chem, 2010. 285(22): p. 17098-111. 74. Zhao, T.T., T.E. Graber, L.E. Jordan, M. Cloutier, S.M. Lewis, I. Goulet, J. Cote, and M. Holcik, hnRNP A1 regulates UV-induced NF-kappaB signalling through 47 destabilization of cIAP1 mRNA. Cell Death Differ, 2009. 16(2): p. 244-52. 75. Lewis, S.M., A. Veyrier, N. Hosszu Ungureanu, S. Bonnal, S. Vagner, and M. Holcik, Subcellular relocalization of a trans-acting factor regulates XIAP IRES-dependent translation. Mol Biol Cell, 2007. 18(4): p. 1302-11. 76. Lee, K.M., M.K. Hwang, D.E. Lee, K.W. Lee, and H.J. Lee, Protective effect of quercetin against arsenite-induced COX-2 expression by targeting PI3K in rat liver epithelial cells. J Agric Food Chem, 2010. 58(9): p. 5815-20. 77. Dolatabadi, J.E., A.A. Jamali, M. Hasanzadeh, and Y. Omidi, Quercetin Delivery into Cancer Cells with Single Walled Carbon Nanotubes. IJBBB, 2011. 1(1): p. 21-25. 78. Chavez, E. and A. Cuellar, ATP Complexes with the ATPase inhibitor quercetin. Life Sci, 1980. 27(16): p. 1477-82. 79. Martin, M.W., A.J. O'Sullivan, and B.D. Gomperts, Inhibition by cromoglycate and some flavonoids of nucleoside diphosphate kinase and of exocytosis from permeabilized mast cells. Br J Pharmacol, 1995. 115(6): p. 1080-6. 80. Gupta, K. and D. Panda, Perturbation of microtubule polymerization by quercetin through tubulin binding: a novel mechanism of its antiproliferative activity. Biochemistry, 2002. 41(43): p. 13029-38. 81. Tate, A., S. Isotani, M.J. Bradley, R.A. Sikes, R. Davis, L.W. Chung, and M. Edlund, Met-Independent Hepatocyte Growth Factor-mediated regulation of cell adhesion in human prostate cancer cells. BMC Cancer, 2006. 6: p. 197. 82. Ginisty, H., H. Sicard, B. Roger, and P. Bouvet, Structure and functions of nucleolin. J Cell Sci, 1999. 112 ( Pt 6): p. 761-72. 83. Fuentealba, R.A., M. Udan, S. Bell, I. Wegorzewska, J. Shao, M.I. Diamond, C.C. Weihl, and R.H. Baloh, Interaction with polyglutamine aggregates reveals a Q/N-rich domain in TDP-43. J Biol Chem, 2010. 285(34): p. 26304-14. 84. Chae, M.J., H.Y. Sung, E.H. Kim, M. Lee, H. Kwak, C.H. Chae, S. Kim, and W.Y. Park, Chemical inhibitors destabilize HuR binding to the AU-rich element of TNF-alpha mRNA. Exp Mol Med, 2009. 41(11): p. 824-31. 85. Grisolia, S., V. Rubio, B. Feijoo, and J. Mendelson, Inhibition of lactic dehydrogenase and of pyruvate kinase by low concentrations of quercetin. Physiol Chem Phys, 1975. 7(5): p. 473-5. 86. Dihal, A.A., H. van der Woude, P.J. Hendriksen, H. Charif, L.J. Dekker, L. Ijsselstijn, V.C. de Boer, G.M. Alink, P.C. Burgers, I.M. Rietjens, R.A. Woutersen, and R.H. Stierum, Transcriptome and proteome profiling of colon mucosa from quercetin fed F344 rats point to tumor preventive mechanisms, increased mitochondrial fatty acid degradation and decreased glycolysis. Proteomics, 2008. 8(1): p. 45-61. 48 87. Nagai, N., A. Nakai, and K. Nagata, Quercetin suppresses heat shock response by down regulation of HSF1. Biochem Biophys Res Commun, 1995. 208(3): p. 1099-105. 88. Zanini, C., G. Giribaldi, G. Mandili, F. Carta, N. Crescenzio, B. Bisaro, A. Doria, L. Foglia, L.C. di Montezemolo, F. Timeus, and F. Turrini, Inhibition of heat shock proteins (HSP) expression by quercetin and differential doxorubicin sensitization in neuroblastoma and Ewing's sarcoma cell lines. J Neurochem, 2007. 103(4): p. 1344-54. 89. Miyamoto, N., H. Izumi, R. Miyamoto, H. Kondo, A. Tawara, Y. Sasaguri, and K. Kohno, Quercetin induces the expression of peroxiredoxins 3 and 5 via the Nrf2/NRF1 transcription pathway. Invest Ophthalmol Vis Sci, 2011. 52(2): p. 1055-63. 90. Rix, U. and G. Superti-Furga, Target profiling of small molecules by chemical proteomics. Nat Chem Biol, 2009. 5(9): p. 616-24. 91. Wang, C., J. Zhou, S. Wang, M. Ye, C. Jiang, G. Fan, and H. Zou, Combined comparative and chemical proteomics on the mechanisms of levo-tetrahydropalmatine-induced antinociception in the formalin test. J Proteome Res, 2010. 9(6): p. 3225-34. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/36185 | - |
dc.description.abstract | 檞黃素是一種普遍存在於蔬果和穀物中的植物性生物黃酮,已經被用在治療慢性攝護腺炎病患。槲黃素是天然的抗組織胺、抗發炎劑、抗氧化劑,還具有抗癌的功效。據研究報導,槲黃素可以誘導攝護腺癌細胞凋亡和抑制癌細胞的生長,並且是具有選擇性的殺死癌細胞而不影響到正常細胞。我們已經從文獻知道槲黃素會影響許多機制,但我們想更進一步了解是否還有我們尚未發現的機制與未知的槲黃素標靶蛋白,使得槲黃素能夠阻礙腫瘤細胞的生長。我們應用了最近新興的化學蛋白體學技術去找尋在攝護腺癌細胞中會與槲黃素交互作用的蛋白。化學蛋白體學是結合了傳統藥物親和層析和質譜儀的生物資訊分析技術以鑑定蛋白。在我們的研究結果中,我們發現hnRNP A1與槲黃素有交互作用,並在後續的體外實驗,以免疫沉澱、西方墨點法、和濾紙結合實驗確定了hnRNP A1和槲黃素之間直接的結合。我們的研究指出,槲黃素與hnRNP A1的結合會阻礙hnRNP A1在細胞核質間往返的能力,造成hnRNP A1堆積在細胞質中,進而阻礙mRNA進行轉譯,影響了抗凋亡蛋白的表現。隨後,細胞內蛋白的不平衡及抗凋亡蛋白的減少則造成癌細胞的死亡。我們對於「槲黃素-hnRNP A1-攝護腺癌細胞」提出新的機制,發現槲黃素與hnRNP A1之間的關連,並更加清楚了解槲黃素分子的作用機轉與可能的副作用。hnRNP A1以後可能可以作為新的藥物標靶蛋白,以用來治療復發性的非男性荷爾蒙依賴型攝護腺癌。同時,我們建立起化學蛋白體學技術平台,可以應用到各種藥物分子和疾病上,幫助了解藥物分子機制及新藥物的開發。 | zh_TW |
dc.description.abstract | Quercetin is a plant-derived flavonoid found in fruits, vegetables, leaves and grains, and it is one of the pharmaceutical molecules used to treat patients with chronic prostatitis. Quercetin had been reported that it could induce cell apoptosis and inhibit cell growth in PC-3 cells and also enhance its anti-cancer efficacy when combining other dietary phytoestrogens. It appears to be a selective inhibitor of cell proliferation of tumor cells instead of normal cells. There were many mechanisms of quercetin involved, but we want to know if there still are some new pathways to hamper tumor progression that we did not know before. In order to find out the direct molecular targets of quercetin in its medicinal property in prostate cancers, we applied chemical proteomics techniques to reach our goal. Chemical proteomics is a postgenomic version of classical drug affinity chromatography that is coupled to subsequent high-resolution MS and bioinformatic analyses for protein identifications. We identified hnRNP A1 by using quercetin-affinity column and demonstrated a specific interaction between quercetin and hnRNPA1 by immunoprecipitation, immunoblotting and in vitro binding experiments. There were many studies indicated that aberrant mRNA processing, nuclear export, splicing and translation would cause imbalance of protein homeostasis and high risk of cancer occurring. Our studies pointed out the interaction of hnRNPA1 and quercetin impairs hnRNPA1’s nucleocytoplasmic shuttling and having impacts on the translation of mRNAs related to cell anti-apoptosis and cell proliferation. We connect the link of quercetin- hnRNPA1- prostate cancer, and try to clarify the mechanism of quercetin treatment to PC-3 cells and finally tumor growth decreased. Our study is a promising example and powerful platform to elucidate a potential drug’s target proteins and might apply to further drug designs to strength the specificity and selectivity. | en |
dc.description.provenance | Made available in DSpace on 2021-06-13T07:53:16Z (GMT). No. of bitstreams: 1 ntu-100-R98442016-1.pdf: 1462419 bytes, checksum: 24c182c5a75ce42fc14e89f734ee1d9a (MD5) Previous issue date: 2011 | en |
dc.description.tableofcontents | 謝誌 i
摘要 ii Abstract iii 縮寫 vi 第一章 導論 1 第一節 攝護腺癌 (prostate cancer) 與目前的治療 1 1.1 攝護腺癌研究之流行病學 1 1.2 攝護腺癌的症狀及診斷 1 1.3 攝護腺癌的治療與預後 2 1.4 人類攝護腺癌細胞株 3 第二節 槲黃素 (quercetin) 3 2.1 類黃酮化合物 (flavonoid) 與槲黃素 3 2.2 槲黃素之生物利用度 4 2.3 槲黃素之功效 4 第三節 化學蛋白體學 (chemical proteomics) 6 第四節 hnRNP A1的功能及其重要性 8 第五節 研究動機與策略 9 第二章 實驗材料 10 第一節 攝護腺癌細胞的培養 19 1.1 培養基 (medium) 的配置 19 1.2 細胞的培養 19 1.3 細胞的計數 19 第二節 化學蛋白體學 19 2.1 槲黃素親和層析 (Quercetin Afiinity Chromatography) 19 2.2 蛋白質濃度測定 20 2.3 TCA沉澱蛋白 21 2.4 十二烷基磺酸鈉—聚丙烯醯胺膠體電泳分析 (SDS-PAGE) 21 2.5膠體原位酵素切割及蛋白質鑑定 22 2.6 西方墨點法 23 第三節 hnRNP A1重組蛋白的表現與純化 24 3.1 使用大腸桿菌表現重組蛋白 24 3.2重組蛋白hnRNP A1的純化 24 第四節 免疫螢光染色 25 4.1玻片標本前處理 25 4.2細胞玻片標本製作 25 第五節 免疫蛋白沉澱 26 第六節 建立wild type和F peptide 突變之hnRNP A1重組質體 26 6.1建立wild type hnRNP A1重組質體 27 6.2建立F peptide mutant hnRNP A1重組質體 27 第七節 細胞轉染 28 第四章 實驗結果 29 第一節 鑑定槲黃素在攝護腺癌細胞 (PC-3) 內的目標蛋白 29 1.1 槲黃素抑制PC-3細胞的生長 29 1.2 以化學蛋白體學鑑定槲黃素的目標蛋白 29 1.3 西方墨點法驗證 29 1.4 體外結合實驗 (in vitro binding assay) 30 第二節 槲黃素與hnRNP A1對PC-3細胞的影響 30 2.1 槲黃素處理造成hnRNP A1堆積在細胞質 30 2.2 槲黃素處理使hnRNP A1與Trn1的結合減少 31 2.3 F peptide磷酸化與否不影響槲黃素和hnRNP A1的結合 31 2.4 槲黃素與M9 domain和F peptide的結合 32 2.5 槲黃素和hnRNP A1的結合對mRNA的影響 33 第五章 討論 34 第一節 槲黃素目標蛋白之分析 34 1.1 hnRNP A1 34 1.2 EF-1α和nm23 35 1.3 vinculin 36 1.4 nucleolin與其他RNA結合蛋白 36 1.5 其他 37 第二節 化學蛋白體學的優缺點 38 2.1 化學蛋白體學的優點及應用性 38 2.2 化學蛋白體學的缺點及限制性 38 第三節 研究總結與未來展望 39 第六章 參考文獻 41 附圖與說明 48 附錄 59 | |
dc.language.iso | zh-TW | |
dc.title | 利用化學蛋白體學鑑定hnRNP A1為槲黃素之目標蛋白與其對攝護腺腫瘤細胞之影響探討 | zh_TW |
dc.title | Chemical proteomics reveals hnRNPA1 as a quercetin target and its effects in PC-3 cell | en |
dc.type | Thesis | |
dc.date.schoolyear | 99-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 梁有志,林君榮,孔繁璐 | |
dc.subject.keyword | 攝護腺癌,化學蛋白體學,槲黃素,hnRNP A1, | zh_TW |
dc.subject.keyword | prostate cancer,chemical proteomics,quercetin,hnRNP A1, | en |
dc.relation.page | 64 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2011-07-21 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 生物化學暨分子生物學研究所 | zh_TW |
顯示於系所單位: | 生物化學暨分子生物學科研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-100-1.pdf 目前未授權公開取用 | 1.43 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。